Zheng Quan Shi Bao Wang
Search documents
风范股份:拟3.825亿元收购炎凌嘉业51%股权
Zheng Quan Shi Bao Wang· 2026-01-26 12:40
人民财讯1月26日电,风范股份(601700)1月26日公告,公司与北京炎凌嘉业智能科技股份有限公司 (简称"炎凌嘉业")现有股东北京机器人产业发展投资基金(有限合伙)等签署了《股份收购协议》,公司 以自有及自筹资金3.825亿元收购炎凌嘉业51%股权。本次交易完成后,炎凌嘉业将成为公司的控股子 公司,并纳入公司合并报表范围。业绩承诺人承诺在业绩承诺期2026年、2027年、2028年内标的公司每 年合并报表归属于母公司所有者的税后净利润分别不低于人民币4000万元、6000万元、8000万元。若业 绩未达预期,业绩承诺赔偿金额上限是本次收购的交易收购价款总额。 ...
亚信安全:收到政府补助680万元
Zheng Quan Shi Bao Wang· 2026-01-26 12:40
人民财讯1月26日电,亚信安全(688225)1月26日公告,公司于近日收到政府补助680万元,属于与收益 相关的政府补助。 ...
格科微:股东拟减持不超0.19%公司股份
Zheng Quan Shi Bao Wang· 2026-01-26 12:40
人民财讯1月26日电,格科微(688728)1月26日公告,持股6.34%的股东Hopefield Holding Limited(简 称"Hopefield")拟通过集中竞价交易或大宗交易方式减持其所持有的公司股份数量合计不超过500万股, 即合计减持不超过公司总股本的0.19%。 ...
康缘药业:获得运脾化痰通窍颗粒药物临床试验批准通知书
Zheng Quan Shi Bao Wang· 2026-01-26 12:36
Core Viewpoint - Kangyuan Pharmaceutical (600557) has received approval from the National Medical Products Administration for clinical trials of its product aimed at treating children's adenoid hypertrophy with spleen deficiency and phlegm obstruction, which could fill a clinical gap in this area [1] Group 1: Product Development - The approved product is a traditional Chinese medicine formulation designed to promote spleen function, resolve phlegm, and open the orifices [1] - Currently, there are no approved traditional Chinese medicines for treating children's adenoid hypertrophy, which primarily relies on chemical drugs such as nasal corticosteroids, leukotriene receptor antagonists, antihistamines, and immunomodulators [1] Group 2: Market Potential - The successful launch of this product could significantly enhance clinical value and address an unmet medical need in pediatric care [1]
四方新材:2025年预亏3亿元左右
Zheng Quan Shi Bao Wang· 2026-01-26 12:31
Core Viewpoint - The company Sifang New Materials (605122) is expected to report a net loss of approximately 300 million yuan for the fiscal year 2025, indicating an increase in losses compared to the previous year [1] Financial Performance - The projected operating revenue for 2025 is around 1 billion yuan [1] - The decline in the real estate sector has significantly impacted the demand for the company's concrete products, with a reported 29.4% decrease in new construction area in Chongqing from January to December 2025 [1] Market Conditions - The primary market for the company's ready-mixed concrete is Chongqing, where the downturn in the real estate industry has led to a substantial reduction in product demand [1] - The cost of key raw materials for ready-mixed concrete has decreased at a slower rate than the selling prices, resulting in a decline in gross profit margins for the company's concrete sales [1]
万东医疗:选举王建国为董事长
Zheng Quan Shi Bao Wang· 2026-01-26 12:25
人民财讯1月26日电,万东医疗(600055)1月26日公告,董事长马赤兵因个人原因申请辞去公司董事 长、董事、董事会战略委员会成员及召集人、董事会薪酬与考核委员会成员职务。离任后,马赤兵将不 在公司及控股子公司任职。1月26日,公司召开第十届董事会第十三次会议,选举王建国为第十届董事 会董事长,任期自公司第十届董事会第十三次会议审议通过之日起至公司第十届董事会任期届满之日 止。 ...
盛视科技:2025年净利同比预降50.26%—64.55%
Zheng Quan Shi Bao Wang· 2026-01-26 12:25
人民财讯1月26日电,盛视科技(002990)1月26日发布业绩预告,预计2025年归母净利6200万元—8700 万元,同比下降50.26%—64.55%。公司2025年业绩变动的原因:(1)受结算周期影响,部分项目回款延 后,公司需计提资产减值准备;(2)公司拓展战略性新型业务致业务整体毛利率有所下降;(3)2025年, 公司实施了2024年限制性股票激励计划,确认的股份支付费用较于去年同期增加;(4)2025年,公司加 大新业务研发投入,研发费用增加。 ...
用户侧光储解决方案提供商硕日新能启动上市辅导
Zheng Quan Shi Bao Wang· 2026-01-26 12:25
1月23日,证监会官网显示,深圳硕日新能科技股份有限公司(简称"硕日新能")在深圳证监局上市辅导 备案,辅导机构为中信建投(601066)。 凭借多年的技术积累与创新,硕日新能已发展成为全球领先的用户侧光储解决方案提供商,并成功获评 国家级专精特新重点"小巨人"企业。财政部、工业和信息化部公示了2024年度国家级专精特新重点"小 巨人"企业结果,硕日新能成功入选。据了解,国家级专精特新"小巨人"企业已处于优质中小企业高质 量发展的顶端,而国家级专精特新重点"小巨人"企业则是在此基础上进一步遴选出的行业翘楚。 同时,硕日新能获得国际权威认证机构T VNORD目击实验室认可资质。T VNORD目击实验室是专门针 对具备有独立检测能力的客户自身的实验室进行目击测试认可的一个资质鉴定项目。该项目有助于提升 被认可实验室的检测能力,同时在一定程度上为客户提供了检测的便利性,有效缩短企业运送样品与等 待测试的项目周期,提高光储企业产品认证的效率,进一步提升产品市场竞争力。 股权结构上,硕日新能控股股东为陈勇,其直接持有公司30.09%股权。 公开资料显示,硕日新能专注于用户侧的能源控制、能源转换、能源存储、能源数字四大核 ...
8亿投资海光信息,豪赚1200亿,成都国资跻身“最强捕手”
Zheng Quan Shi Bao Wang· 2026-01-26 12:23
Core Insights - Chengdu's government venture capital investment in Haiguang Information has yielded over 120 billion yuan in returns, establishing a new benchmark for local state-owned investment [1][2][3] - The investment has transformed Haiguang Information into a 700 billion yuan domestic CPU giant, showcasing the potential of government-backed investments in strategic emerging industries [1][2][3] Investment Performance - Chengdu's state-owned enterprises invested 8.125 billion yuan in Haiguang Information, which has now a market value exceeding 121.7 billion yuan, representing a return of over 150 times [2][3][4] - The investment has generated significant financial returns, with Chengdu's state-owned enterprises having already recouped their initial investment through previous share sales [2][3][4] Strategic Implications - The success of Haiguang Information illustrates the effectiveness of government venture capital in driving local economic growth, job creation, and tax revenue [1][2][3] - Chengdu's model of "investment—appreciation—financing—investment" may serve as a reference for other local governments seeking to enhance their industrial landscape [1][2][3] Company Development - Haiguang Information, originally established in Tianjin, relocated to Chengdu after receiving investment from Chengdu's government, which facilitated its growth and development in the CPU sector [10][11][12] - The company has become the only domestic enterprise with x86 processor technology authorization, further solidifying its position in the semiconductor industry [12][13] Financial Restructuring - Chengdu's investment has positively impacted the financial statements of its state-owned enterprises, allowing them to maintain profitability despite challenges in other sectors [18][21] - The increase in the market value of Haiguang Information has enabled Chengdu's state-owned enterprises to issue bonds and secure financing for further investments [21][23] Industry Impact - Chengdu has emerged as a significant hub for semiconductor companies, with over 400 integrated circuit enterprises established, contributing to a growing industry scale [24] - The success of Haiguang Information has positioned Chengdu as a key player in the national semiconductor landscape, influencing local and regional economic strategies [24]
佑驾创新斩获13亿元智驾定点,规模化量产再提速
Zheng Quan Shi Bao Wang· 2026-01-26 12:23
1月26日,佑驾创新(02431.HK)宣布,于近日新获某知名车企的项目定点通知,将为其面向国内及海 外市场的广泛车型开发并提供一系列先进的智能驾驶产品。 据悉,项目全生命周期订单总金额约为13亿元人民币,计划于2026年中正式启动量产。佑驾创新表示, 此次标志性项目定点验证了公司技术实力与产品可靠性,是公司在乘用车智能化领域的重大突破,也是 公司智能驾驶技术走向全球市场的关键一步。 据悉,该车企在中国市场拥有广泛的用户基础。官方数据显示,2025年其销量领跑市场,以超百万辆成 绩稳居行业头部阵营。佑驾创新获得行业头部车企认可,代表其产品在性能、可靠性及合规性上均达到 国际主流标准,具备服务全球市场的能力。而项目覆盖车型与市场范围广、全生命周期价值高,体现出 客户对公司创新研发与量产交付的信心。 当前,汽车智能化浪潮席卷全球,随着搭载智驾功能的车型加速推向市场,产业链上下游企业迎来新的 发展窗口。其中,具备技术、工程化与成本综合优势的头部智驾企业,将站在更广阔的国际市场,为智 能汽车产业的高质量发展贡献力量。作为产业出海浪潮的先行者,佑驾创新已在海外市场深度布局、多 点开花。 佑驾创新是国内首批助力整车厂通过 ...